Brief: FDA Grants Accelerated Approval To Combination Of Avutometinib And Defactinib For Kras-Mutated Recurrent Low-Grade Serous Ovarian Cancer
08/05/2025 17:13
May 8 (Reuters) - FDA: FDA GRANTS ACCELERATED APPROVAL TO COMBINATION OF AVUTOMETINIB AND DEFACTINIB FOR KRAS-MUTATED RECURRENT LOW-GRADE SEROUS OVARIAN CANCER ((Reuters.Briefs@thomsonreuters.com;))